You are here

Technology in Cancer Research & Treatment
Share

Technology in Cancer Research & Treatment

2017 Impact Factor: 1.646
2017 Ranking: 194/222 in Oncology
Source: Journal Citation Reports®, 2018 release, a Clarivate Analytics product; Indexed in PubMed: MEDLINE; Indexed in PubMed Central

Executive Editor
Jennifer Lovick, PhD SAGE Publishing, Thousand Oaks, CA USA


eISSN: 15330338 | ISSN: 15330346 | Current volume: 16 | Current issue: 6 Frequency: Bi-monthly

Journal Highlights

  • Impact Factor: 1.646
  • Indexed In: Clarivate Analytics: Social Science Index Expanded (Web of Science), PubMed Central, Medline, SCOPUS, EMBASE, Index Medicus, and the DOAJ
  • Fast and double-blind peer review by dedicated Associate Editors and Editorial Board Members
  • Global visibility due to international audience of multidisciplinary researchers
  • Publication is subject to payment of an article processing charge (APC)
  • Submit here


Technology in Cancer Research and Treatment (TCRT)
is an open access, peer-reviewed journal which focuses on developments in the prevention, diagnosis, treatment, and monitoring of cancer. Please see the Aims and Scope tab for further information.

This journal is a member of the Committee on Publication Ethics (COPE).



Submission Information

Submit your manuscript at https://mc.manuscriptcentral.com/tcrt.

Please see the Submission Guidelines tab for more information on how to submit your article to the journal.

Open access article processing charge (APC) information

Publication in the journal is subject to payment of an article processing charge (APC). The APC serves to support the journal and ensures that articles are freely accessible online in perpetuity under a Creative Commons license.

The APC for this journal is currently $2000 USD.

The article processing charge (APC) is payable only if your article is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested. Please see further details here.

Contact

Please direct any queries to jennifer.lovick@sagepub.com.


Why Publish Open Access with TCRT

  • Visibility and Impact: Anyone anywhere in the world can read, use and cite your research
  • Rigorous Standards: Double-blind peer review policy
  • Speed: Less than 2 months from submission to first decision and 4 weeks from acceptance to online publication
  • Flexibility: No page limits or page charges, and authors can publish full data sets, figures, tables, etc
  • Copyright: Authors retain copyright under a Creative Commons License

Useful Links

Other information

This journal changed its publication mode from subscription to open access in 2016.

Technology in Cancer Research and Treatment (TCRT) is a JCR-ranked, broad-spectrum, open access, peer-reviewed publication whose aim is to provide researchers and clinicians with a platform to share and discuss developments in the prevention, diagnosis, treatment, and monitoring of cancer.

Article Types and Topics of Interest
TCRT welcomes original research (both basic and clinical studies), reviews, and commentaries. We encourage submissions relating to advances in the following areas:

Preventative or Diagnostic
  • Biomarkers (genes, genetic abnormalities, RNA, proteins, hormones, enzymes)
  • Methods of biomarker detection
  • Cancer biology (cell and molecular biology, immune response, tumor biology, tumor microenvironment)
  • Genetic (DNA damage and repair, epigenetics, gene regulation)
  • Proteomics, Genomics, Systems Biology
  • Epidemiology
  • Imaging technologies (CT scan, MRI, X-ray, Ultrasound)
  • Nuclear medicine scan (Bone, PET, Thyroid, MUGA, Gallium)
  • Biopsy (endoscopic, needle)
  • Emerging technologies
  • Novel applications of existing technologies

 

Treatment or Monitoring

  • Stem cell transplantation
  • Precision/Personalized medicine, Targeted therapy (antibodies, small-molecule drugs)
  • Immunotherapy (adoptive cell transfer, BCG, cytokines, gene therapy, gene transfer, monoclonal antibodies, oncolytic virotherapy, vaccines)
  • Surgery (open or minimally-invasive)
  • Chemotherapy
  • Hormone therapy
  • Radiation therapy (external beam or internal), Brachytherapy
  • Cryosurgery/Cryotherapy
  • Laser therapy (laser-induced interstitial thermotherapy (LITT), interstitial laser photocoagulation)
  • Hyperthermia therapy/Thermal therapy/Thermotherapy
  • Photodynamic therapy (PDT)
  • Irreversible electroporation (IRE)
  • Emerging technologies or novel applications of existing ones

Click here to see a selection of the latest papers published in TCRT

Manuscript Submission

Executive Editor
Jennifer K. Lovick, PhD SAGE Publishing, Thousand Oaks, CA USA
Founding Editor
Mukti H. Sarma, PhD University at Albany - SUNY, New York, USA
Associate Editor - Chemo/Combinatorial Therapies
Timo L.M. Ten Hagen, PhD Erasmus MC, Netherlands
Associate Editor - Cryotherapy/Biothermal Technology
Yoed Rabin, DSc Carnegie Mellon University, Pittsburgh, USA
Associate Editor - Immunotherapy
Satiro De Oliveira David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Associate Editor - Medical Physics and Imaging
Kujtim Latifi, PhD Moffitt Cancer Center, Tampa, FL USA
Xin Zhang, PhD University of Arkansas for Medical Sciences, Little Rock, AR, USA
Associate Editor - Methylation
Mukesh Verma, PhD National Institutes of Health, Bethesda, Maryland, USA
Associate Editor - Radiation and Cancer Biology
Robert Griffin, PhD University of Arkansas, Little Rock
Associate Editor - Thermal Therapies
Maja Cemazar, PhD Institute of Oncology, Ljubljana, Slovenia
Truls E. Bjerklund Johansen Oslo University Hospital, Norway
Associate Editor - Tumor Biology
Amir Goldkorn USC Norris Comprehensive Cancer Center & Keck School of Medicine, CA, USA
Paola Maycotte Centro de Investigación Biomédica de Oriente, Puebla, Mexico
Consulting Editor
Umair Shafique, MSc SAGE Publishing, Thousand Oaks, CA USA
Editorial Board
Abass Alavi, MD Perelman School of Medicine, University of Pennsylvania, USA
Robert Alfano, PhD The City College Of New York, CUNY
Filippo Alongi, MD Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy
Mario Ammirati, MD, MBA St. Rita Medical Center/Mercy Health, Lima OH, USA
John G. Baust, PhD State University of New York, Binghamton, USA
Stewart Becker, PhD New York University, Langone Medical Center, USA
Dzevad Belkic, PhD Karolinska Institute, Stockholm, Sweden
Karen Belkic, MD, PhD Claremont Graduate University, California, USA
Max K. Bulsara The University of Notre Dame, Australia
George A. Calin, MD, PhD The University of Texas M.D. Anderson Cancer Center, Houston, USA
Jeffrey J. Chalmers, PhD Ohio State University, Columbus, USA
Gregory Czarnota, MD, PhD Sunnybrook Research Institute, University of Toronto, Canada
Hadassa Degani, PhD The Weizmann Institute of Science, Israel
Ayman El-Baz, PhD University of Louisville, Kentucky, USA
Adel K. El-Naggar, MD, PhD The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Antonella Fogliata, PhD Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Andrew A. Gage, MD State University of New York, Buffalo, USA
Roberto Gambari, PhD University of Ferrara, Italy
Sanjiv Sam Gambhir Stanford University, Stanford, CA, USA
A.H. Gandjbakhche, PhD National Institutes of Health, Bethesda, Maryland, USA
Uwe Haberkorn, PhD University of Heidelberg, Germany
Garret M. Hampton, PhD Genomics Institute of the Novartis Research Foundation, California, USA
Samir Hanash, MD, PhD Fred Hutchinson Cancer Research Center, Washington, USA
Richard Heller, PhD Old Dominion University, Virginia
Dwight Heron, MD University of Pittsburgh Cancer Institute, Pennsylvania, USA
David Isaacson, PhD Rensselaer Polytechnic Institute, New York
Samie R. Jaffrey, MD, PhD Cornell University, New York, USA
Kewal K. Jain, MD Pharmabiotech, Switzerland
Tomas Kron, PhD Peter MacCallum Cancer Center, Australia
David Larson, MD, PhD University of California, San Francisco, USA
Frederick Locke, MD Moffitt Cancer Center, Florida
Jay Loeffler, MD, FACR, FASTRO Massachusetts General Hospital, Boston, USA
Kenneth Lundstrom, PhD PanTherapeutics, Switzerland
Lijun Ma, PhD University of California, San Francisco, USA
Paulette McCormick, PhD University at Albany - SUNY, New York, USA
William M. Mendenhall, MD Shands Cancer Center, Florida, USA
Arlan H. Mintz, MD University of Pittsburgh, Pennsylvania, USA
Filippo Molinari, PhD Politecnico di Torino, Italy
Sten Myrehaug, PhD Sunnybrook Health Sciences Centre, University of Toronto, Canada
Subir Nag, MD Kaiser Permanente, Santa Clara, California, USA
Orhan Nalcioglu, PhD, FIEEE, FAAPM University of California, Irvine, USA
Yin Kwee Ng, PhD Nanyang Technological University, Singapore
Dattatreyudu Nori, MD, FACR New York Presbyterian Hospital, USA
Dilini Pinnaduwage, PhD University of California, San Francisco, USA
Tomasz Piotrowski Greater Poland Cancer Center, Poznan, Poland
Veena N. Rao, PhD Morehouse School of Medicine, Atlanta, GA, USA
William F. Regine, MD University of Maryland, Baltimore, USA
Thomas Reid, MD National Cancer Institute, Bethesda, Maryland, USA
David Roberge, MD McGill University, Canada
Berkman Sahiner, PhD University of Michigan, Ann Arbor, USA
Daniel Scherman, PhD INSERM, France
Reinhard Schulte, MD Loma Linda University, California, USA
Eva M. Sevick-Muraca, PhD University of Texas Health Sciences Center, Houston, USA
Richard Simpson, PhD University of Arizona, Tucson, AZ, USA
Keshav Singh, PhD University of Alabama, Birmingham, USA
Hany Soliman, MD, FRCPC Sunnybrook Research Institute, University of Toronto, Canada
Luis Souhami, MD McGill University, Canada
Gunnar Steineck University of Gothenburg, Gothenburg, Sweden
H. Cuneyt Ulutin, MD, PhD Yeni Yuzyil University, Turkey
Xiaoying Wang, PhD Tianjin University of Traditional Chinese Medicine, Tianjin, China
James S. Welsh, MS, MD, FARCO Stritch School of Medicine Loyola University- Chicago, USA
Andrew Wroe, PhD, DABR Loma Linda University Medical Center, USA
Sue S. Yom, MD, PhD University of California, San Francisco, USA
Cedric Yu, PhD University of Maryland, Baltimore, USA
Wenwei Yu, PhD Chiba University, Japan
Baohong Yuan, PhD University of Texas, Arlington, USA
Ning J. Yue, PhD, FAAPM Rutgers Robert Wood Johnson Medical School, New Jersey, USA
Marco Zaider, PhD Memorial Sloan Kettering Cancer Center, New York, USA
Nikolai Zhelev, PhD, CBiol, EurProBiol Abertay University, Scotland
Wei Zheng, PhD The University of Texas M.D. Anderson Cancer Center, Houston, USA
Dandan Zheng, PhD University of Nebraska Medical Center, USA
Abdullah Faruk Zorlu, MD Hacettepe University, Turkey
Editorial Review Board
Michael D. Chuong Baptist Health South Florida, Miami Cancer Institute, Florida, USA
Lui Ng Hong Kong University, Hong Kong, China
Chun-Chien Shieh The University of Sydney, Australia
Govindarajan Srimathveeravalli Memorial Sloan Kettering Cancer Center, New York, USA
Chunhao Wang Duke University Medical Center, Durham, North Carolina, USA
Ching-Feng Weng University of Maryland at Baltimore, USA
  • EMBASE/Excerpta Medica
  • Index Medicus
  • MEDLINE
  • Science Citation Index Expanded (Web of Science)
  • Scopus
  • This Journal is a member of the Committee on Publication Ethics.

    This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing,
    and Publication of Scholarly Work in Medical Journals
    formulated by the International Committee of
    Medical Journal Editors (ICMJE).

    Please read the guidelines below then visit the journal’s submission site
    https://mc.manuscriptcentral.com/TCRT to upload your manuscript. Please note that manuscripts not
    conforming to these guidelines may be returned.

    Only manuscripts of sufficient quality that meet the aims and scope of Technology in Cancer Research &
    Treatment
    will be reviewed.

    As part of the submission process you will be required to warrant that you are submitting your original
    work, that you have the rights in the work, that you are submitting the work for first publication in the
    Journal and that it is not being considered for publication elsewhere and has not already been published
    elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of
    any copyright works not owned by you.

    Please Read the Manuscript Submission Guidelines below before submitting your manuscript here:
    SUBMIT MANUSCRIPT

     

    1. Open Access
    2. Article processing charge (APC)
    3. What do we publish?
      3.1 Aims & scope
      3.2 Article types
      3.2.1 Original research articles
      3.2.2 Review articles
      3.2.3 Opinion pieces
      3.3 Writing your paper
      3.3.1 Making your article discoverable 
    4. Editorial policies
      4.1 Peer Review Policy
      4.2 Authorship
      4.3 Acknowledgements
      4.4 Funding
      4.5 Declaration of conflicting interests
      4.6 Research ethics and patient consent
      4.7 Clinical Trials
      4.8 Reporting guidelines
      4.9 Data
    5. Publishing policies
      5.1 Publication ethics
      5.1.1 Plagiarism
      5.1.2 Prior publication
      5.2 Contributor's publishing agreement
    6. Preparing your manuscript
      6.1 Word processing formats
      6.1.1 Title and Authors (On a separate title page)
      6.1.2 Manuscript Preparation
      6.2 Artwork, figures and other graphics
      6.3 Supplementary material
      6.4 Reference style
      6.5 English language editing services
    7. Submitting your manuscript
      7.1 How to submit your manuscript
      7.2 Title, keywords and abstracts
      7.3 Information required for completing your submission
      7.4 ORCID
      7.5 Permissions
    8. On acceptance and publication
      8.1 SAGE Production
      8.2 Continuous publication
      8.3 Promoting your article
    9. Further information

    1. Open Access

    Technology in Cancer Research & Treatment is an open access, peer-reviewed journal. Each article
    accepted by peer review is made freely available online immediately upon publication, is published
    under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the
    journal are covered by the collection of article processing charges which are paid by the funder,
    institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to
    the journal.

    For general information on open access at SAGE please visit the Open Access page or view our Open
    Access FAQs
    .

    Back to top

    2. Article processing charge (APC)

    If, after peer review, your manuscript is accepted for publication, a one-time article processing charge
    (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely
    available online in perpetuity under a Creative Commons licence.

    Beginning January 1, 2018, the APC for TCRT will be $1250. This APC will apply to any accepted articles
    with original submission dates of January 1, 2018 or after. Accepted articles with original submission
    dates before January 1, 2018 will be assessed the APC of $1000.

    Back to top

    3. What do we publish?

    3.1 Aims & scope

    Before submitting your manuscript to Technology in Cancer Research & Treatment, please
    ensure you have read the Aims & Scope.

    3.2 Article types

    3.2.1 Original research articles

    Original, in-depth, research articles must follow the Aims & Scope of TCRT with
    emphasis on prevention, diagnosis, treatment, and monitoring of cancer. TCRT does not
    impose word or figure limits, but does reserve the right to ask for manuscripts to be
    edited and/or shortened.

    3.2.2 Review articles

    Review Articles should report on the existing state of understanding in a specific
    research area and/or topic. TCRT does not impose word or figure limits, but does
    reserve the right to ask for manuscripts to be edited and/or shortened.

    3.2.3 Opinion pieces

    Opinion Pieces should not exceed four printed pages. Papers in this section should
    present a new vision or perspective of recent developments. They may also critically
    address recent publications from any journal. In the latter case, the criticized authors
    will be given a chance to write a prompt response. Articles in this section should address
    unsolved controversies arising in current research.

    3.3 Writing your paper

    The SAGE Author Gateway has some general advice and on how to get published, plus links to
    further resources.

    3.3.1 Making your article discoverable 

    When writing up your paper, think about how you can make it discoverable. The title,
    keywords and abstract are key to ensuring readers find your article through search
    engines such as Google. For information and guidance on how best to title your article,
    write your abstract and select your keywords, have a look at this page on the Gateway:
    How to Help Readers Find Your Article Online

    Back to top

    4. Editorial policies

    4.1 Peer review policy

    The journal’s policy is to have manuscripts reviewed by two expert reviewers. Technology in
    Cancer Research & Treatment utilizes a double-blind peer review process in which the reviewer
    and authors’ names and information are withheld from the other. All manuscripts are reviewed
    as rapidly as possible, while maintaining rigor. Reviewers make comments to the author and
    recommendations to the Managing Editor who then makes the final decision. 

    **When uploading your manuscript, please make sure no identifying information is included
    in the main document, including in the acknowledgements, funding and conflict of interest
    statements. If any of these statements contain identifying information, please put the
    statements on the title page.

    Technology in Cancer Research & Treatment is committed to delivering high quality, fast peerreview
    for your paper, and as such has partnered with Publons. Publons is a third party service
    that seeks to track, verify and give credit for peer review. Reviewers for Technology in Cancer
    Research & Treatment
    can opt in to Publons in order to claim their reviews or have them
    automatically verified and added to their reviewer profile. Reviewers claiming credit for their
    review will be associated with the relevant journal, but the article name, reviewer’s decision and
    the content of their review is not published on the site. For more information visit the Publons
    website.

    The Editor or members of the Editorial Board may occasionally submit their own manuscripts for
    possible publication in the journal. In these cases, the peer review process will be managed by
    alternative members of the Board and the submitting Editor/Board member will have no
    involvement in the decision-making process.

    4.2 Authorship

    Papers should only be submitted for consideration once consent is given by all contributing
    authors. Those submitting papers should carefully check that all those whose work contributed
    to the paper are acknowledged as contributing authors.
    The list of authors should include all those who can legitimately claim authorship. This is all
    those who:

    (i) Made a substantial contribution to the concept or design of the work; or acquisition,
    analysis or interpretation of data,
    (ii) Drafted the article or revised it critically for important intellectual content,
    (iii) Approved the version to be published,
    (iv) Each author should have participated sufficiently in the work to take public
    responsibility for appropriate portions of the content.

    Authors should meet the conditions of all of the points above. Each author should have
    participated sufficiently in the work to take public responsibility for appropriate portions of the
    content.

    When a large, multicentre group has conducted the work, the group should identify the
    individuals who accept direct responsibility for the manuscript. These individuals should fully
    meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone
    does not constitute authorship, although all contributors who do not meet the criteria for
    authorship should be listed in the Acknowledgments section. Please refer to the International
    Committee of Medical Journal Editors (ICMJE) authorship guidelines
    for more information on
    authorship.

    4.3 Acknowledgements

    All contributors who do not meet the criteria for authorship should be listed in an
    Acknowledgements section. Examples of those who might be acknowledged include a person
    who provided purely technical help, or a department chair who provided only general support. 

    4.3.1 Writing assistance

    Individuals who provided writing assistance, e.g. from a specialist communications company, do
    not qualify as authors and so should be included in the Acknowledgements section. Authors
    must disclose any writing assistance – including the individual’s name, company and level of
    input – and identify the entity that paid for this assistance.
    It is not necessary to disclose use of language polishing services.

    Please supply any personal acknowledgements separately to the main text to facilitate
    anonymous peer review.

    4.4 Funding

    Technology in Cancer Research & Treatment requires all authors to acknowledge their funding in
    a consistent fashion under a separate heading. Please visit the Funding Acknowledgements
    page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in
    the event of funding, or state that: This research received no specific grant from any funding
    agency in the public, commercial, or not-for-profit sectors.

    4.5 Declaration of conflicting interests

    It is the policy of Technology in Cancer Research & Treatment to require a declaration of
    conflicting interests from all authors enabling a statement to be carried within the paginated
    pages of all published articles.

    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of
    your manuscript, after any acknowledgements and prior to the references. If no conflict exists,
    please state that ‘The Author(s) declare(s) that there is no conflict of interest’.

    For guidance on conflict of interest statements, please see the ICMJE recommendations.

    4.6 Research ethics and patient consent

    Medical research involving human subjects must be conducted according to the World Medical
    Association Declaration of Helsinki
    .

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct,
    Reporting, Editing, and Publication of Scholarly Work in Medical Journals
    , and all papers
    reporting animal and/or human studies must state in the methods section that the relevant
    Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure 
    that you have provided the full name and institution of the review committee, in addition to the
    approval number.

    For research articles, authors are also required to state in the methods section whether
    participants provided informed consent and whether the consent was written or verbal.
    Information on informed consent to report individual cases or case series should be included in
    the manuscript text. A statement is required regarding whether written informed consent for
    patient information and images to be published was provided by the patient(s) or a legally
    authorized representative.
    Please also refer to the ICMJE Recommendations for the Protection of Research Participants.

    All research involving animals submitted for publication must be approved by an ethics
    committee with oversight of the facility in which the studies were conducted. The journal has
    adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals
    published by the International Association of Veterinary Editors.

    4.7 Clinical trials

    Technology in Cancer Research & Treatment conforms to the ICMJE requirement that clinical
    trials are registered in a WHO-approved public trials registry at or before the time of first patient
    enrolment as a condition of consideration for publication. The trial registry name and URL, and
    registration number must be included at the end of the abstract.

    4.8 Reporting guidelines

    The relevant EQUATOR Network reporting guidelines should be followed depending on the type
    of study. For example, all randomized controlled trials submitted for publication should include
    a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should
    be uploaded with your submission as a supplementary file. Systematic reviews and metaanalyses
    should include the completed PRISMA flow chart as a cited figure and the completed
    PRISMA checklist should be uploaded with your submission as a supplementary file. The
    EQUATOR wizard can help you identify the appropriate guideline.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.

    Back to top

    5. Publishing policies

    5.1 Publication ethics

    SAGE is committed to upholding the integrity of the academic record. We encourage authors to
    refer to the Committee on Publication Ethics’ International Standards for Authors and view the
    Publication Ethics page on the SAGE Author Gateway.

    5.1.1 Plagiarism

    Technology in Cancer Research & Treatment and SAGE take issues of copyright infringement,
    plagiarism or other breaches of best practice in publication very seriously. We seek to protect
    the rights of our authors and we always investigate claims of plagiarism or misuse of published
    articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted
    articles may be checked with duplication-checking software. Where an article, for example, is
    found to have plagiarized other work or included third-party copyright material without
    permission or with insufficient acknowledgement, or where the authorship of the article is
    contested, we reserve the right to take action including, but not limited to: publishing an
    erratum or corrigendum (correction); retracting the article; taking up the matter with the head
    of department or dean of the author's institution and/or relevant academic bodies or societies;
    or taking appropriate legal action.

    5.1.2 Prior publication

    If material has been previously published, it is not generally acceptable for publication in a SAGE
    journal. However, there are certain circumstances where previously published material can be
    considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in
    doubt, contact the Editor at the address given below.

    5.2 Contributor's publishing agreement

    Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s
    Publishing Agreement. Technology in Cancer Research & Treatment publishes manuscripts
    under Creative Commons licenses. The standard license for the journal is Creative Commons by
    Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without
    permission as long as the work is properly referenced and the use is non-commercial. For more
    information, you are advised to visit SAGE's OA licenses page.

    Alternative license arrangements are available, for example, to meet particular funder
    mandates, made at the author’s request. 

    Back to top

    6. Preparing your manuscript

    6.1 Word processing formats

    Preferred formats for the text and tables of your manuscript are Word DOC, RTF, XLS. LaTeX files
    are also accepted. The text should be double-spaced throughout and with a minimum of 3cm for
    left and right hand margins and 5cm at head and foot. Text should be standard 10 or 12 point.
    TCRT follows IUPAC-IUB nomenclature. Word and (La)Tex templates are available on the
    Manuscript Submission Guidelines page of our Author Gateway.

    6.1.1 Title and Authors (On a separate title page)

    • Title should be in upper and lower case (Do not use all UPPERcase)
    • Author first name (or initials), middle initial, and last name (surname, family name)
    • and degree(s)
    • Affiliations: use 1, 2, etc. after the degree
    • Put an * after the name of the corresponding author

    6.1.2 Manuscript preparation

    Abstract
    The abstract should be 250-300 words and should reflect the results. Describe the
    purpose of the study and briefly explain how the study was performed. Summarize the
    most important observations and their significance. Do not use abbreviations in the
    abstract.

    Keywords
    Following the abstract, please list 5-6 keywords for indexing the article. Keywords, along
    with the abstract and title, are central to ensuring that readers can search for and find
    your article online. For this reason, to aid in search-ability, words in the title should not
    be used as keywords. For keyword suggestions, please visit the National Library of
    Medicine’s Medical Subject Headings (MeSH®) website
    .

    Abbreviations
    Please included a list of all abbreviations used in the manuscript. These should be listed
    in alphabetical order. (Example: MRI, Magnetic Resonance Imaging; RT, Radiation
    Therapy)

    Introduction
    Provide background that allows readers outside the discipline to understand significance
    of the study. Include a brief review of important literature in the relevant field.
    References cited should be in parentheses ( ).

    Materials and Methods
    Please do not use numbering or subheadings. Describe in detail any new methods or
    protocols used, in order that other investigators can replicate the study. Older, betterknown
    methods may be cited in references, but should be described enough that the
    reader may understand the method.

    Specific Reporting Guidelines
    Medical research involving human subjects must be conducted according to the World
    Medical Association Declaration of Helsinki. Submitted manuscripts should conform to
    the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of
    Scholarly Work in Medical Journals, and all papers reporting animal and/or human
    studies must state in the methods section that the relevant Ethics Committee or
    Institutional Review Board provided (or waived) approval. Please ensure that you have
    provided the full name and institution of the review committee, in addition to the
    approval number. For research articles, authors are also required to state in the
    methods section whether participants provided informed consent and whether the
    consent was written or verbal.

    Human Subject Research
    Methods section using human subject must include ethics statements that
    specify:

    • The name of the approving institutional review board (IRB) or equivalent
      committees. If approval was not obtained, a detailed statement
      explaining the reason is required.
    • Nature of Informed consent – oral or written. If oral, how the consent
      was documented should be stated in the manuscript. If written consent
      was not obtained, the reasons should be stated in themanuscript.

    Animal Research
    Methods section of the manuscript reporting animal research must include
    ethics statements that specify the relevant ethics committee approving the
    research, and associate permit number(s). If ethical approval was not required,
    reasons should be stated in the manuscript. Relevant details to minimize
    suffering of the animal should be mentioned.

    Cell Line Research
    Methods section should state the origin of the cell lines. In cases of established
    cell lines, in addition to origin, the commercial source should be given. If
    previously unpublished new cell lines were used, the source should be
    disclosed.

    Results
    Explain how the results relate to the premise of the study especially in relation to
    previous related studies and how the present study results might have potential in
    directing future research.

    Discussion
    Describe the interpretation of the data.

    Conclusion (Optional)
    Avoid overemphasizing the conclusion.

    Conflict of Interests Statement
    At the end of the manuscript, before the Acknowledgements section, statements
    related to conflicts of interests must appear.

    Acknowledgements
    List the names of the individuals along with the contributors who have participated in
    some capacity but cannot be qualified as authors.

    Funding
    Disclose if any funds were received to conduct the research.

    References
    Technology in Cancer Research & Treatment adheres to AMA reference style. In the
    references section (i.e., bibliography), please list references in the same order as they
    were cited in the manuscript. When a website is cited as a reference, provide the date
    that the website was last accessed.

    Unpublished data and personal correspondence may be cited as references within the
    text itself and are not to be included in the list of references. Authors are fully
    responsible for the accuracy of references used, and all text quoted. Manuscripts
    submitted in any other format may delay the publication of your article.

    6.2 Artwork, figures and other graphics

    All figures and illustrations should contain clean and clear graphics, and must be submitted
    electronically in their original format (e.g., png, jpeg, tif).

    Line art must have a resolution of at least 900 dpi (dots per inch). Electronic photographs,
    radiographs, CT scans, MRIs, all medical imaging, and all scanned images must have a resolution
    of at least 300 dpi. If fonts are used in the artwork, they must be embedded in the files. Color
    images must be created/scanned and saved and submitted as CMYK files. Please note that
    artwork downloaded from the internet (JPEG or GIF files) cannot be used.

    Ensure that fonts are clear and easy to read should the figures be resized to a 1-column or 2-
    column format during the layout process of publication. Please use the following guidelines
    when preparing your image files:

    Example of Figure

    For graphics reprinted from another source, provide written permission for reproduction from
    the copyright owner. Include full credit in the manuscript’s text, figure legends, and/or in the
    acknowledgement section, as appropriate.

    Embed all images in the manuscript and submit separate files for each image in the original
    format it was created (e.g., png, jpeg, tiff).

    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please
    visit SAGE’s Manuscript Submission Guidelines

    Figures supplied in color will appear in color online.

    Equations
    If your manuscript is in .docx format and contains equations, make sure the equations are
    editable. Equations must be placed in brackets [ ].

    Tables
    Tables should have a concise title and should not occupy more than one printed page. Indicate
    in red where to place the Figures and Tables. Create tables in Word format within the
    manuscript.

    Use Arabic numerals to name tables (e.g. Table 1). Cite tables in the text in consecutive order.
    For each table, provide a table heading that clearly and concisely explains the content of the
    table. Indicate table footnotes with lower-case letters in superscript font. Place the information
    for the footnote beneath the body of the table.

    If a table will be submitted as a separate document, the filename should contain the surname of
    the first author and match its label in the manuscript (e.g., SMITH Table 1).

    6.3 Supplementary material

    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images
    etc) alongside the full-text of the article. These will be subjected to peer-review alongside the
    article. For more information please refer to our guidelines on submitting supplementary files,
    which can be found within our Manuscript Submission Guidelines page. 

    6.4 Reference style

    Technology in Cancer Research & Treatment adheres to the AMA reference style. Please review
    the guidelines on AMA to ensure your manuscript conforms to this reference style.

    If you use EndNote to manage references, you can download the AMA output file here.

    6.5 English language editing services

    Authors seeking assistance with English language editing, translation, or figure and manuscript
    formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit
    SAGE Language Services on our Journal Author Gateway for further information. 

    Back to top

    7. Submitting your manuscript

    7.1 How to submit your manuscript

    Technology in Cancer Research & Treatment is hosted on SAGE Track, a web based online
    submission and peer review system powered by ScholarOne™ Manuscripts. Visit
    https://mc.manuscriptcentral.com/TCRT to login and submit your article online. 

    IMPORTANT: Please check whether you already have an account in the system before trying to
    create a new one. If you have reviewed or authored for the journal in the past year it is likely
    that you will have had an account created. For further guidance on submitting your manuscript
    online please visit ScholarOne Online Help.

    7.2 Title, keywords and abstracts

    Please supply a title, short title, an abstract and keywords to accompany your article. The title,
    keywords and abstract are key to ensuring readers find your article online through online search
    engines such as Google. Please refer to the information and guidance on how best to title your
    article, write your abstract and select your keywords by visiting the SAGE Journal Author
    Gateway for guidelines on How to Help Readers Find Your Article Online

    7.3 Information required for completing your submission

    Provide full contact details for the corresponding author including email, mailing address and
    telephone numbers. Academic affiliations are required for all co-authors. These details should
    be presented separately to the main text of the article to facilitate anonymous peer review.

    You will be asked to provide contact details and academic affiliations for all co-authors via the
    submission system and identify who is to be the corresponding author. These details must
    match what appears on your manuscript. At this stage please ensure you have included all the
    required statements and declarations and uploaded any additional supplementary files
    (including reporting guidelines where relevant).

    7.4 ORCID

    As part of our commitment to ensuring an ethical, transparent and fair peer review process
    SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID
    provides a persistent digital identifier that distinguishes researchers from every other researcher
    and, through integration in key research workflows such as manuscript and grant submission,
    supports automated linkages between researchers and their professional activities ensuring that
    their work is recognized.

    We encourage all authors to add their ORCIDs to their SAGE Track accounts and include their
    ORCIDs as part of the submission process. If you don’t already have one you can create one
    here.

    7.5 Permissions

    Authors are responsible for obtaining permission from copyright holders for reproducing any
    illustrations, tables, figures or lengthy quotations previously published elsewhere. For further
    information including guidance on fair dealing for criticism and review, please visit our
    Frequently Asked Questions on the SAGE Journal Author Gateway.

    Back to top

    8. On acceptance and publication

    If your paper is accepted for publication after peer review, you will first be asked to complete the
    contributor’s publishing agreement. Once your manuscript files have been checked for SAGE Production,
    the corresponding author will be asked to pay the article processing charge (APC) via a payment link.
    Once the APC has been processed, your article will be prepared for publication and can appear online
    within an average of 30 days. Please note that no production work will occur on your paper until the
    APC has been received.

    8.1 SAGE Production

    Your SAGE Production Editor will keep you informed as to your article’s progress throughout the
    production process. Proofs will be sent by PDF to the corresponding author and should be
    returned promptly. Authors are reminded to check their proofs carefully to confirm that all
    author information, including names, affiliations, sequence and contact details are correct, and
    that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there
    are any changes to the author list at this stage all authors will be required to complete and sign
    a form authorizing the change

    8.2 Online publication

    One of the many benefits of publishing your research in an open access journal is the speed to
    publication. With no page count constraints, your article will be published online in a fully
    citable form with a DOI number as soon as it has completed the production process. At this time
    it will be completely free to view and download for all. 

    8.3 Promoting your article

    Publication is not the end of the process! You can help disseminate your paper and ensure it is
    as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help
    you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.
    In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich,
    share, and measure the impact of their article. Find out how to maximize your article’s impact
    with Kudos
    .

    Back to top

    9. Further information

    Any correspondence, queries or additional requests for information on the Manuscript Submission
    process should be sent to the Managing Editor as follows:

    Jennifer Lovick, PhD, Managing Editor | Jennifer.Lovick@sagepub.com 

    Back to top